Misery In Myelofibrosis: Pacritinib Setback A Boost For Jakafi
With the commercial opportunity in the myelofibrosis market expected to double to over $1bn in the next five years, competition to Incyte/Novartis's Jakafi seems further away than ever as CTI BioPharma pulls the European regulatory filing for pacritinib.
You may also be interested in...
Firm publishes final data from a Phase III study showing the safety-troubled JAK2/FLT3 inhibitor performs better than Jakafi in reducing spleen size. Ongoing dose-finding study will determine the regulatory path forward.
The JAK inhibitor momelotinib meets some endpoints but misses others in two late-stage clinical studies in myelofibrosis, a condition that has proved recalcitrant to various new approaches, leaving Incyte/Novartis’s marketed product ruxolitinib as one of the few successes.
Shares in Geron dropped by nearly 20% to $2.30 on NASDAQ on Sept. 12 following interim clinical data for its lead product, the anticancer imetelstat, from trials conducted by its partner Janssen.